Stryker’s Joint Replacement division has received U.S. FDA 510(k) market clearance for its cementless Mako Total Knee with Triathlon Tritanium
Triathlon Tritanium combines the kinematics of Stryker’s market leading Triathlon knee implant with the latest in highly porous biologic fixation technology. The innovative tibial baseplate and metal-backed patella components are enabled by Stryker’s proprietary AMagine additive manufacturing technology and are SOMA-designed.
With the newly cleared system Stryker is tapping into the rising popularity of cementless procedures. The company says its Mako Total Knee with Triathlon Tritanium expands the current robotics offering to include a cementless option. The result for orthopaedic surgeons is a more predictable surgical experience combined with increased operating room efficiency, biologic fixation and an alternative to bone cement.
“With the rise in demand for cementless knee technology, we believe this new offering can have a positive impact on procedural efficiency and patient outcomes,” said Stuart Simpson, President, Stryker’s Joint Replacement division. “We’re excited to continue to lead in robotic technology and combine two of our most advanced and differentiated products to provide surgeons with the ability to transform orthopaedic surgery.”
Source: PR Newswire